Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION).
Authors
Sarah Elizabeth Fenton
Northwestern University, Chicago, IL
Sarah Elizabeth Fenton , Rachel Springsdorf , Siobhan Kenny , Lauren Bere , Ashley Ross , Masha Kocherginsky , Maha H. A. Hussain , David James VanderWeele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04737109
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 174)
DOI
10.1200/JCO.2023.41.6_suppl.174
Abstract #
174
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.
First Author: David James VanderWeele
Poster
2018 Gastrointestinal Cancers Symposium
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
First Author: Akihito Kawazoe
Poster
2016 Genitourinary Cancers Symposium
ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone (DP) chemotherapy for metastatic castration resistant prostate cancer (mCRPC).
First Author: Simon J. Crabb
Poster
2023 ASCO Annual Meeting
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.
First Author: Scott T. Tagawa